Non-Hodgkin Lymphoma | Specialty

Dr. Horwitz Discusses the Results of the ECHELON-2 Study

December 13th 2018

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the ECHELON-2 study in patients with CD30+ peripheral T-cell lymphomas (PTCL).

Selinexor Promotes Deep, Durable Responses in Relapsed/Refractory DLBCL

December 11th 2018

Selinexor monotherapy induced deep and durable responses in the phase IIb SADAL study of patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplantation.

Robust Future Ahead for Stem Cell Transplants

December 6th 2018

Although many new drugs have been introduced for treating patients with hematologic malignancies, stem cell transplantation remains a vital part of the therapeutic paradigm, particularly for multiple myeloma and non-Hodgkin lymphoma.

Update Details Brentuximab Vedotin Survival Benefit in CD30+ PTCL

December 5th 2018

The addition of brentuximab vedotin to chemotherapy led to a clinically meaningful improvement in progression-free and overall survival in patients with CD30-expressing peripheral T-cell lymphoma.

Dr. Poeschel on 6 Versus 4 Cycles of R-CHOP in Frontline DLBCL

December 4th 2018

Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.

Dr. Andreadis on the Treatment of Relapsed DLBCL

December 4th 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with relapsed diffuse large B-cell lymphoma.

Lenalidomide/Rituximab Improves PFS in Indolent Non-Hodgkin Lymphoma

December 3rd 2018

The R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) reduced the risk of disease progression or death by 54% versus rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Antibody-Drug Conjugate Impresses in Relapsed/Refractory DLBCL

December 3rd 2018

The addition of a CD79b-targeted antibody-drug conjugate to bendamustine and rituximab more than doubled overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma.

Reduced Treatment Equally Effective in DLBCL

December 2nd 2018

Treating younger patients with low-risk diffuse large B-cell lymphoma with 2 fewer frontline cycles of R-CHOP greatly reduced toxicity without sacrificing efficacy, according to findings from the FLYER trial.

Tisagenlecleucel Benefit Sustained in DLBCL Follow-Up

December 2nd 2018

Tisagenlecleucel continued to demonstrate durable objective response rates with a median of 19 months of follow-up for patients with relapsed or refractory diffuse large B-cell lymphoma, according to updated findings from the phase II JULIET study.

FDA Approves Brentuximab Vedotin for Frontline CD30+ PTCL

November 16th 2018

The FDA has approved brentuximab vedotin for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.

FDA Grants Brentuximab Vedotin Breakthrough Designation for Frontline CD30+ PTCL

November 16th 2018

The FDA has granted brentuximab vedotin a breakthrough therapy designation for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.

Dr. Andreadis Discusses the Role of Ibrutinib in DLBCL

November 14th 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with diffuse large B-cell lymphoma.

Emerging Agents, Strategies Propel Progress in Follicular Lymphoma

November 8th 2018

Novel agents and treatment strategies continue to expand the armamentarium in follicular lymphoma, explains John P. Leonard, MD, in a session at the 36th Annual CFS®.

FDA Grants Selinexor Fast Track Designation for Relapsed/Refractory DLBCL

November 8th 2018

The FDA has granted a fast track designation to selinexor for the treatment of patients with previously treated diffuse large B-cell lymphoma who are ineligible to receive high-dose chemotherapy with stem cell rescue or CAR T-cell therapy.

FDA Approval Sought for Brentuximab Vedotin in Frontline CD30+ PTCL

November 6th 2018

A supplemental biologics license application has been submitted to the FDA for the use of brentuximab vedotin (Adcetris) in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.

Dr. Roschewski on the Use of DA-EPOCH-R in Burkitt Lymphoma

November 2nd 2018

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the use of dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in patients with Burkitt lymphoma.

UCSF Expert Highlights Progress in Lymphoma Landscape

October 29th 2018

Lawrence D. Kaplan, MD, discusses recent updates and next steps in the expanding paradigm of Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma.

Future Directions for CAR-T Therapy

October 29th 2018

Expanding the Role of CAR T in non-Hodgkin Lymphoma

October 29th 2018